Ozempic and Wegovy are made by the same company, Novo Nordisk, and they contain the same active drug, semaglutide. They are not two versions of one product by accident. Ozempic holds an FDA approval for type 2 diabetes, and Wegovy holds a separate approval for chronic weight management, at different doses and with different clinical trials behind each. That single decision, to keep one molecule under two names, explains most of the confusion people run into over cost, coverage, and which one a doctor writes.
Who makes Ozempic, and is it the same as Wegovy?
For anyone searching who makes Ozempic, the short answer is Novo Nordisk, a Danish drug maker that has produced insulin and diabetes therapies for roughly a century. The same firm developed Wegovy. Both drugs are semaglutide, a GLP-1 receptor agonist that mimics a gut hormone influencing blood sugar and appetite. The FDA maintains a public notice explaining that these products share the active ingredient while carrying distinct approved uses, which is worth reading before assuming they are interchangeable.
The reason they exist as separate brands is regulatory, not marketing sleight of hand. A drug approval in the United States is tied to a specific use, a specific population, and a specific set of studies. Diabetes and obesity are treated as different conditions with different evidence requirements, so a company that wants a semaglutide product for each has to run each program and file each application on its own.
What is different between the two products?
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active drug | Semaglutide | Semaglutide |
| Approved use | Type 2 diabetes | Chronic weight management |
| Maximum weekly dose | Lower | Higher |
| Primary trial program | Diabetes glucose control | STEP weight-loss trials |
| Typical coverage category | Diabetes benefit | Anti-obesity benefit |
The doses matter. Wegovy is approved at a higher maximum than Ozempic, because the weight-management studies were run at that level. That difference is written into the product labels, which is why the two are not simply swapped for one another. The prescribing information for Wegovy and for Ozempic lays out the separate dosing schedules and the specific populations each was studied in.
Why did the weight-loss version need its own trials?
Because approval for one condition does not carry over to another. Wegovy earned its weight-management label through the STEP program, a set of studies in people with overweight or obesity. The STEP 3 trial paired semaglutide with intensive behavioral therapy and reported substantial weight loss beyond the behavioral program alone. The STEP 4 trial tested what happened when people who had already lost weight either continued the drug or switched to placebo, and continuation preserved the loss while stopping led to regain. The STEP 8 trial compared weekly semaglutide against daily liraglutide, an older GLP-1 drug, and semaglutide produced greater average weight reduction.
One finding is easy to miss and important. An extension analysis of the STEP 1 trial followed participants after they stopped semaglutide and found that much of the lost weight returned over the following year. That is a fact about how the drug works, not a footnote. These medications manage a chronic condition rather than cure it, a point echoed in current pharmacotherapy guidance for obesity management, which frames long-term use as the expected model rather than a short course.
Can a doctor just prescribe Ozempic for weight loss?
It happens, and it is worth being honest about. During periods when Wegovy was hard to get, some prescribers used Ozempic off label for weight loss. That is legal for a licensed clinician, but it is not the labeled use, and the weight-management evidence sits with Wegovy at its studied doses. Off-label use also tends to complicate insurance, because a diabetes drug billed for a non-diabetes reason is a common trigger for denial. My view is that the branding split, confusing as it looks, usually pushes people toward the product that actually matches their goal and their coverage.
How does the two-brand setup affect what you pay?
This is where the split stops being trivia. Diabetes drugs and anti-obesity drugs are treated differently by insurers and, for Medicare, by law. A plan may cover Ozempic readily for a diabetes diagnosis while excluding Wegovy because it will not cover the anti-obesity category at all. Same molecule, same manufacturer, opposite answers. Checking which benefit category applies to your situation matters more than comparing the two brands head to head.
When brand coverage falls through, people start weighing self-pay routes, and this is where the field gets crowded. Novo Nordisk runs its own direct programs, and telehealth services including Ro, Hims and Hers, Henry Meds, and physician-supervised practices such as the one described in this in-depth guide present themselves as ways to reach a prescriber and a price without going through a plan. Some of these route to brand-name semaglutide, and some route to compounded semaglutide, which is a meaningfully different thing.
Where does compounded semaglutide fit?
Compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule as Ozempic and Wegovy, but it has not been through the approval process that produced the STEP trial evidence or the published labels. The clinical obesity literature has been working to sharpen how the condition itself is defined and diagnosed, and that precision matters most when the product in hand was not studied under an approved application. Compounded versions can offer a predictable cash price, but that price buys away some of the regulatory assurance that comes with the brands. Whether that trade makes sense is a conversation for a prescriber who knows the case, not a decision to make on price alone.
Key takeaways
- Novo Nordisk makes both Ozempic and Wegovy, and both are the same drug, semaglutide.
- The brands are split because each holds a separate FDA approval, for diabetes and for weight management, at different doses.
- Wegovy’s weight-loss claim rests on the STEP trials, which also showed weight regain after stopping.
- Insurance often treats the two very differently, so the benefit category matters more than the brand name.
Frequently asked questions
Who makes Ozempic and Wegovy?
Both are made by Novo Nordisk, a Danish pharmaceutical company. They share the same active drug, semaglutide, but are approved and marketed under different brand names for different uses.
Are Ozempic and Wegovy the same drug?
They contain the same molecule, semaglutide, but they are separate FDA approvals. Ozempic is approved for type 2 diabetes, and Wegovy is approved for chronic weight management, with different maximum doses.
Can Ozempic be prescribed for weight loss?
Prescribing a diabetes drug off label for weight loss happens, but it is not the labeled use. Wegovy is the semaglutide product carrying the weight management approval and the trial evidence behind it.
Why price the same molecule under two names?
Each brand has its own approval, trials, dosing, and insurance treatment. Diabetes and obesity are handled differently by coverage and by law, which is why one company keeps two products.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It may use the same molecule but has not gone through the approval process behind the brands.
